APRI (Aprinoia Therapeutics) Tax Provision: $-0.89 Mil (TTM As of Dec. 2023)


What is Aprinoia Therapeutics Tax Provision?

Aprinoia Therapeutics APRI Tax Provision is $-0.89 Mil as of Dec. 2023.

Aprinoia Therapeutics's tax provision for the six months ended in Dec. 2023 was $-0.83 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.89 Mil.

Aprinoia Therapeutics Tax Provision Historical Data

* Premium members only.

The historical data trend for Aprinoia Therapeutics's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics Tax Provision Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Tax Provision
0.00 -0.02 -0.89

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Tax Provision 0.00 -0.01 -0.01 -0.05 -0.83

Aprinoia Therapeutics Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of $-0.89 Mil mean?
Aprinoia Therapeutics (APRI) has a Tax Provision of $-0.89 Mil as of Dec. 2023. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Aprinoia Therapeutics and its competitors.
Is Aprinoia Therapeutics' Tax Provision too high?
Aprinoia Therapeutics' current Tax Provision is $-0.89 Mil.
How does Aprinoia Therapeutics' Tax Provision compare to ?
Aprinoia Therapeutics' Tax Provision of $-0.89 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Biotechnology company?
A good Tax Provision depends on the Biotechnology industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Aprinoia Therapeutics and its competitors. Aprinoia Therapeutics's current Tax Provision is $-0.89 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprinoia Therapeutics stock overvalued right now?
Aprinoia Therapeutics (APRI) has a current Tax Provision of $-0.89 Mil. The current Tax Provision is $-0.89 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For Aprinoia Therapeutics (APRI), the current Tax Provision is $-0.89 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprinoia Therapeutics Business Description

Comparable Companies
Address 245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.